Home Tags Trodelvy

Tag: Trodelvy

Gilead Finalizes Acquisition of Immunomedics

Earlier today Foster City, California-based Gilead Sciences confirmed that it had completed the previously announced transaction to acquire Immunomedics for approximately U.S. $ 21...

ESMO 2020: In Heavily-pretreated Metastatic Urothelial Cancer Sacituzumab Govitecan Shows 27%...

Heavily-pretreated, cisplatin-eligible, patients benefit from treatment with sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy®; Immunomedics).This is the conclusion from an analysis of data from the pivotal...
ESMO 2017 - 3

ESMO 2020: Sacituzumab Govitecan Shows Encouraging Early-Stage Clinical Results in Brain...

A clinical trial (NCT03995706) studying the extent by which sacituzumab govitecan (Trodelvy™; Immunomedics) is able to get into the brain and treat patients with...

Immunomedics and Roche Expand Study Collaboration in First-line Metastatic Triple-negative Breast...

Immunomedics and Roche have agreed to expand their clinical trial collaboration to evaluate sacituzumab govitecan-hziy (Trodelvy™), a Trop-2-directed antibody conjugated to a topoisomerase I...

Everest Medicines’ Licensing Partner Immunomedics Receives FDA Accelerated Approval for Sacituzumab...

Everest Medicines' U.S.-based licensing partner Immunomedics earlier today confirmed that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA)...

FDA Grants Accelerated Approval for Sacituzumab Govitecan in Metastatic Triple-negative Breast...

The U.S. Food and Drug Administration (FDA) has approved sacituzumab govitecan* (Trodelvy™; Immunomedics) for the treatment of adult patients with metastatic triple-negative breast cancer...